Perioperative immunotherapy for non-small cell lung cancer: practical application of emerging data and new challenges

Angelica D'Aiello,Brendon Stiles,Nitin Ohri,Benjamin Levy,Perry Cohen,Balazs Halmos

DOI: https://doi.org/10.1016/j.cllc.2024.02.004

IF: 4.84

2024-02-15

Clinical Lung Cancer

Abstract:Immune checkpoint inhibition, with or without chemotherapy, is an established standard of care for metastatic non-small cell lung cancer (NSCLC). For locally advanced NSCLC treated with chemoradiotherapy, consolidation immunotherapy has dramatically improved outcomes. Recently, immunotherapy has also been established as a valuable component of treatment for resectable NSCLC with pembrolizumab, atezolizumab, and nivolumab all approved for use in this setting (Table 1). As more results read out from ongoing perioperative clinical trials, navigating treatment options will likely become increasingly complex for the practicing oncologist. In this paper, we distill key outcomes from major perioperative trials and highlight current knowledge gaps. In addition, we provide practical considerations for incorporating perioperative immunotherapy into the clinical management of operable NSCLC.

oncology